EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Outcomes of Patients With Diffuse Systemic Sclerosis Eligible for Autologous Stem Cell Transplantation Treated With Conventional Therapy

Kate Gregory iD, Dylan Hansen, Ross Penglase, Diane Apostolopoulos iD, Gene-Siew Ngian, Wendy Stevens, Kathleen Morrisroe iD, Nava Ferdowsi, Laura Ross iD, Jennifer Walker, Helen Cooley, Peter Youssef und 6 weitere

Arthritis & Rheumatology · 2024

DOI: 10.1002/art.42850 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Arthritis & Rheumatology, 2024. Verfasst von Kate Gregory und 17 weiteren Autor:innen. Beteiligte Einrichtung: Monash University and Monash Health, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Scleroderma, Diffuse, Stem Cell Transplantation, Transplantation, Autologous. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Australian Scleroderma Interest Group, Rose Hellaby Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The study objective was to determine the event‐free survival (EFS) of Australian patients with diffuse cutaneous systemic sclerosis (dcSSc) who met eligibility criteria for autologous stem cell transplant (ASCT) in previously published randomized controlled trials but were not treated with ASCT.

Methods

Patients who met inclusion criteria for the Autologous Stem Cell Transplantation International Scleroderma (ASTIS) and Scleroderma: Cyclophosphamide Or Transplantation (SCOT) trials were identified from the multicenter Australian Scleroderma Cohort Study (ASCS). EFS (survival without cardiac, renal, or pulmonary failure or death) at 4 years was assessed. ASCS patients who had already undergone transplantation were excluded from analysis.

Results

Of the 492 patients with dcSSc in the ASCS, 56 met ASTIS inclusion criteria for ASCT (56 of 492 [11.4%]) and 30 met SCOT inclusion criteria (30 of 492 [6.1%]). An additional 11 patients met ASTIS or SCOT inclusion criteria, but they were excluded due to severe organ manifestations. EFS at 4 years in ASCS patients meeting ASTIS inclusion criteria was 83.3% and in ASCS patients meeting SCOT inclusion criteria was 81.2%. EFS at 4 years in ASCS patients who met ASTIS and SCOT inclusion but also exclusion criteria was 46.7% and 45.7%, respectively.

Conclusion

ASCS patients meeting ASTIS and/or SCOT inclusion criteria who were not treated with ASCT have similar EFS at 4 years as patients receiving ASCT and better EFS than those receiving cyclophosphamide in the ASTIS and SCOT trials. This may reflect confounders unable to be controlled for, including survivor bias, but may also reflect improved standard of care for dcSSc over time.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Scleroderma, DiffuseStem Cell TransplantationTransplantation, AutologousAdultFemaleHumansMaleMiddle AgedAustraliaCohort StudiesCyclophosphamideHematopoietic Stem Cell TransplantationPatient SelectionProgression-Free SurvivalTreatment Outcome

Substanzen

Cyclophosphamide

Autor:innen und Institutionen

  • Monash University and Monash Health, Melbourne, Victoria, Australia.
  • St. Vincent's Hospital, Melbourne, Victoria, Australia.
  • St Vincent's Hospital, St Vincent's Centre for Applied Medical Research, and University of New South Wales, Sydney, New South Wales, Australia.
  • St. Vincent's Hospital, Melbourne, Victoria, Canberra Hospital, Garran, Australian Capital Territory, and University of Melbourne, Melbourne, Victoria, Australia.
  • St. Vincent's Hospital and University of Melbourne, Mebourne, Victoria, Australia.
  • Royal Adelaide Hospital, Adelaide, South Australia, Australia.

ORCID-Profile: Kate Gregory, Diane Apostolopoulos, Kathleen Morrisroe, Laura Ross, Susanna Proudman

Förderung

  • Australian Scleroderma Interest Group
  • Rose Hellaby Trust

Zitieren

APA

Gregory, K., Hansen, D., Penglase, R., Apostolopoulos, D., Ngian, G. S., Stevens, W., Morrisroe, K., Ferdowsi, N., Ross, L., Walker, J., Cooley, H., Youssef, P., Tymms, K., Host, L., Proudman, S., Moore, J., Nikpour, M., & Sahhar, J. (2024). Outcomes of Patients With Diffuse Systemic Sclerosis Eligible for Autologous Stem Cell Transplantation Treated With Conventional Therapy. Arthritis & Rheumatology. https://doi.org/10.1002/art.42850

Vancouver

Gregory K, Hansen D, Penglase R, Apostolopoulos D, Ngian GS, Stevens W, et al. Outcomes of Patients With Diffuse Systemic Sclerosis Eligible for Autologous Stem Cell Transplantation Treated With Conventional Therapy. Arthritis & Rheumatology. 2024. doi:10.1002/art.42850

BibTeX
@article{Gregory2024,
  author = {Gregory, Kate and Hansen, Dylan and Penglase, Ross and Apostolopoulos, Diane and Ngian, Gene-Siew and Stevens, Wendy and Morrisroe, Kathleen and Ferdowsi, Nava and Ross, Laura and Walker, Jennifer and Cooley, Helen and Youssef, Peter and Tymms, Kathleen and Host, Lauren and Proudman, Susanna and Moore, John and Nikpour, Mandana and Sahhar, Joanne},
  title = {Outcomes of Patients With Diffuse Systemic Sclerosis Eligible for Autologous Stem Cell Transplantation Treated With Conventional Therapy},
  journal = {Arthritis & Rheumatology},
  year = {2024},
  doi = {10.1002/art.42850}
}
Kostenlos starten →